Karen Ann White

Karen Ann White, listed as senior executive, appears in our data through filings on GeneDx Holdings Corp. shares, published by SEC (Form 4). Between 25 October 2021 and 25 July 2023, the trades on record add up to 20 filings.

Sales make up the whole of the open-market record (3 sales, €7,901). Outside the open market, there are 1 share grant and 16 option exercises. Since January 2023: no purchases and 1 sale on the market.

On 27 July 2023 came the latest disclosure, an option exercise in GeneDx Holdings Corp. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 3 days. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.